CVE:HEM

Hemostemix Competitors

C$0.48
-0.01 (-2.04 %)
(As of 04/12/2021 02:32 PM ET)
Add
Compare
Today's Range
C$0.47
Now: C$0.48
C$0.49
50-Day Range
C$0.41
MA: C$0.45
C$0.54
52-Week Range
C$0.10
Now: C$0.48
C$0.80
Volume124,996 shs
Average Volume222,319 shs
Market CapitalizationC$22.26 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Hemostemix (CVE:HEM) Vs. EMH, IGX, QPT, CZO, CTX, and KNE

Should you be buying HEM stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Hemostemix, including Emerald Health Therapeutics (EMH), IntelGenx Technologies (IGX), Quest PharmaTech (QPT), Ceapro (CZO), Crescita Therapeutics (CTX), and Kane Biotech (KNE).

Emerald Health Therapeutics (CVE:EMH) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Profitability

This table compares Emerald Health Therapeutics and Hemostemix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Emerald Health TherapeuticsN/AN/AN/A
HemostemixN/AN/AN/A

Valuation & Earnings

This table compares Emerald Health Therapeutics and Hemostemix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Emerald Health TherapeuticsC$13.02 million4.17C$-142,699,488.00C($0.70)-0.38
HemostemixN/AN/AN/AC($0.17)-2.86

Hemostemix has lower revenue, but higher earnings than Emerald Health Therapeutics. Hemostemix is trading at a lower price-to-earnings ratio than Emerald Health Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Emerald Health Therapeutics and Hemostemix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Emerald Health Therapeutics0000N/A
Hemostemix0000N/A

Summary

Emerald Health Therapeutics beats Hemostemix on 2 of the 3 factors compared between the two stocks.

IntelGenx Technologies (CVE:IGX) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares IntelGenx Technologies and Hemostemix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IntelGenx TechnologiesN/AN/AN/A
HemostemixN/AN/AN/A

Earnings and Valuation

This table compares IntelGenx Technologies and Hemostemix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IntelGenx TechnologiesC$1.54 million47.84C$-7,274,150.00C($0.07)-10.15
HemostemixN/AN/AN/AC($0.17)-2.86

Hemostemix has lower revenue, but higher earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Hemostemix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for IntelGenx Technologies and Hemostemix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IntelGenx Technologies0000N/A
Hemostemix0000N/A

Summary

IntelGenx Technologies beats Hemostemix on 2 of the 3 factors compared between the two stocks.

Quest PharmaTech (CVE:QPT) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Quest PharmaTech and Hemostemix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
HemostemixN/AN/AN/A

Earnings and Valuation

This table compares Quest PharmaTech and Hemostemix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00474.71C$109.88 millionC$0.660.17
HemostemixN/AN/AN/AC($0.17)-2.86

Quest PharmaTech has higher revenue and earnings than Hemostemix. Hemostemix is trading at a lower price-to-earnings ratio than Quest PharmaTech, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Quest PharmaTech and Hemostemix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
Hemostemix0000N/A

Summary

Quest PharmaTech beats Hemostemix on 3 of the 3 factors compared between the two stocks.

Ceapro (CVE:CZO) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Ceapro and Hemostemix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
HemostemixN/AN/AN/A

Earnings and Valuation

This table compares Ceapro and Hemostemix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.80C$2.56 millionC$0.0323.94
HemostemixN/AN/AN/AC($0.17)-2.86

Ceapro has higher revenue and earnings than Hemostemix. Hemostemix is trading at a lower price-to-earnings ratio than Ceapro, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Ceapro and Hemostemix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
Hemostemix0000N/A

Summary

Ceapro beats Hemostemix on 3 of the 3 factors compared between the two stocks.

Crescita Therapeutics (TSE:CTX) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Crescita Therapeutics and Hemostemix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crescita TherapeuticsN/AN/AN/A
HemostemixN/AN/AN/A

Earnings and Valuation

This table compares Crescita Therapeutics and Hemostemix's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$15.64 million1.12C$41,296.00C$0.00425.00
HemostemixN/AN/AN/AC($0.17)-2.86

Crescita Therapeutics has higher revenue and earnings than Hemostemix. Hemostemix is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Crescita Therapeutics and Hemostemix, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crescita Therapeutics0000N/A
Hemostemix0000N/A

Summary

Crescita Therapeutics beats Hemostemix on 3 of the 3 factors compared between the two stocks.

Kane Biotech (CVE:KNE) and Hemostemix (CVE:HEM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Profitability

This table compares Kane Biotech and Hemostemix's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kane BiotechN/AN/AN/A
HemostemixN/AN/AN/A

Earnings & Valuation

This table compares Kane Biotech and Hemostemix's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57
HemostemixN/AN/AN/AC($0.17)-2.86

Hemostemix has lower revenue, but higher earnings than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Hemostemix, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Kane Biotech and Hemostemix, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kane Biotech0000N/A
Hemostemix0000N/A

Summary

Kane Biotech beats Hemostemix on 2 of the 3 factors compared between the two stocks.


Hemostemix Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.27-9.4%C$34.02 millionC$13.02 million-0.38
IGX
IntelGenx Technologies
0.9$0.66-13.6%C$30.87 millionC$1.54 million-10.15High Trading Volume
News Coverage
QPT
Quest PharmaTech
0.8$0.11-0.0%C$21.76 millionC$38,871.000.17High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.79-8.9%C$21.65 millionC$16.14 million23.94
CTX
Crescita Therapeutics
0.6$0.85-1.2%C$17.55 millionC$15.64 million425.00
KNE
Kane Biotech
0.4$0.16-6.3%C$14.12 millionC$1.34 million-4.57
GSD
Devonian Health Group
0.5$0.27-3.7%C$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09-5.6%C$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06-0.0%C$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60-0.0%C$10.80 millionC$12.71 million-1.03Gap Up
BTI
Bioasis Technologies
0.7$0.44-11.4%C$10.16 millionC$4.12 million40.00
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75News Coverage
IBT
IBEX Technologies
0.7$0.36-1.4%C$6.94 millionC$5.60 million6.67
IOT
Innovotech
0.8$0.15-3.3%C$6.52 millionC$1.04 million75.00
BCT
BriaCell Therapeutics
0.5$4.90-30.6%C$4.48 millionN/A-1.58High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5$2.95-2.7%C$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.7N/AN/AC$0.00C$267.59 million47.20
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
News Coverage
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.